Request Trial
img_1651
22 October 2019AmericasSarah Morgan

LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda

While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
LSPN Awards 2026 finalists revealed
2 March 2026   Law firms, companies and individuals have been shortlisted across a range of categories, which this year include new awards for excellence in PTAB, trade secrets and medical device work.
Americas
Natera and a rival draw the line under five-year fight
27 February 2026   The companies have agreed to dismiss their long-running patent fight over tumour-informed liquid biopsy technology, closing a high-stakes chapter in the fast-growing MRD testing market—while leaving the door open to future claims.
Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026   As the US Supreme Court prepares to hear arguments in the Hikma and Amarin dispute, the case has drawn a broad coalition of industry support—including the US government and a co-author of the Hatch-Waxman Act itself.


Editor's picks

LSPN Awards 2026 finalists revealed
Americas
LSPN Awards 2026 finalists revealed
2 March 2026

Editor's picks

Americas
LSPN Awards 2026 finalists revealed
2 March 2026

More features

Gowling WLG brings in transactions expert with UK and US experience
LSPN Awards 2026 finalists revealed
Natera and a rival draw the line under five-year fight
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
Eli Lilly escapes $278m payout in biotech licensing dispute
Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices
Wiggin’s new litigation partner deepens ‘technically complex’ offer
Could everyday hospital equipment be the next defence against counterfeit medicines?